Loading…
Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma
Advanced esophago-gastric (OG) adenocarcinomas have a high mortality rate and new therapeutic options are urgently required. Despite recent advances in understanding the molecular characteristics of OG cancers, tumor heterogeneity poses a challenge in developing new therapeutics capable of improving...
Saved in:
| Published in: | Pharmacogenomics 2021-07, Vol.22 (11), p.703-726 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23 |
| container_end_page | 726 |
| container_issue | 11 |
| container_start_page | 703 |
| container_title | Pharmacogenomics |
| container_volume | 22 |
| creator | Fong, Caroline Yk Chau, Ian |
| description | Advanced esophago-gastric (OG) adenocarcinomas have a high mortality rate and new therapeutic options are urgently required. Despite recent advances in understanding the molecular characteristics of OG cancers, tumor heterogeneity poses a challenge in developing new therapeutics capable of improving patient outcomes. Consequently, chemotherapy remains the mainstay of systemic treatment, with the HER2 being the only predictive biomarker routinely targeted in clinical practice. Recent data indicate that immunotherapy will be incorporated into first-line chemotherapy, but further research is required to refine patient selection. This review will summarize the clinical strategies being evaluated to utilize our knowledge of predictive biomarkers with reference to novel therapeutics, and discuss the barriers to implementing precision oncology in OG adenocarcinoma. |
| doi_str_mv | 10.2217/pgs-2020-0090 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8265282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2540725260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23</originalsourceid><addsrcrecordid>eNp1kc-P1SAQx4nRuD_06NVw9IIOU0pfLyZms7qbbOJFz4TSoQ_tgwrtJvvfy8tbN3rwNEP48AHmy9gbCe8RZfdhmYpAQBAAPTxj57JTSuxA4fPaK40CldRn7KKUHwAotYKX7KxREkFpec7sjc2RSglx4kNIB5t_Ui48eZ6pLCkW4mvi4bDkdF_bPWW7PPBCM7k1pMhD5FTSsrdTEpMtaw6O25Ficja7EKvwFXvh7Vzo9WO9ZN8_X3-7uhF3X7_cXn26E0413SpabH2jG-tI4mj7rm-gd34A6fu-laT9oGuVatA4StnRqHsLY-OlwqFrPTaX7OPJu2zDgUZHcc12NksO9VMPJtlg_t2JYW-mdG92qFvcHQXvHgU5_dqorOYQiqN5tpHSVgy2CjpsUUNFxQl1OZWSyT9dI8EcYzE1FnOMxRxjqfzbv9_2RP_JoQL9CfDbutXJu0DRkTmt6olQZ0n_kf8GzFSfEw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2540725260</pqid></control><display><type>article</type><title>Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma</title><source>PubMed Central</source><creator>Fong, Caroline Yk ; Chau, Ian</creator><creatorcontrib>Fong, Caroline Yk ; Chau, Ian</creatorcontrib><description>Advanced esophago-gastric (OG) adenocarcinomas have a high mortality rate and new therapeutic options are urgently required. Despite recent advances in understanding the molecular characteristics of OG cancers, tumor heterogeneity poses a challenge in developing new therapeutics capable of improving patient outcomes. Consequently, chemotherapy remains the mainstay of systemic treatment, with the HER2 being the only predictive biomarker routinely targeted in clinical practice. Recent data indicate that immunotherapy will be incorporated into first-line chemotherapy, but further research is required to refine patient selection. This review will summarize the clinical strategies being evaluated to utilize our knowledge of predictive biomarkers with reference to novel therapeutics, and discuss the barriers to implementing precision oncology in OG adenocarcinoma.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs-2020-0090</identifier><identifier>PMID: 34120461</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Adenocarcinoma - genetics ; Adenocarcinoma - metabolism ; Adenocarcinoma - therapy ; Biomarkers - metabolism ; biomarkers of response ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; esophageal cancer ; Esophageal Neoplasms - genetics ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - therapy ; esophago-gastric adenocarcinoma ; gastric cancer ; gastro-esophageal junction cancer ; Humans ; Immune Checkpoint Inhibitors - administration & dosage ; Immunoconjugates - administration & dosage ; Immunotherapy - methods ; Immunotherapy - trends ; Precision Medicine - methods ; Precision Medicine - trends ; precision oncology ; predictive biomarkers ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Review ; Stomach Neoplasms - drug therapy ; targeted therapy ; Trastuzumab - administration & dosage</subject><ispartof>Pharmacogenomics, 2021-07, Vol.22 (11), p.703-726</ispartof><rights>2021 Future Medicine Ltd</rights><rights>2021 Future Medicine Ltd 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23</citedby><cites>FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23</cites><orcidid>0000-0002-4409-9466 ; 0000-0003-0286-8703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265282/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265282/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34120461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fong, Caroline Yk</creatorcontrib><creatorcontrib>Chau, Ian</creatorcontrib><title>Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>Advanced esophago-gastric (OG) adenocarcinomas have a high mortality rate and new therapeutic options are urgently required. Despite recent advances in understanding the molecular characteristics of OG cancers, tumor heterogeneity poses a challenge in developing new therapeutics capable of improving patient outcomes. Consequently, chemotherapy remains the mainstay of systemic treatment, with the HER2 being the only predictive biomarker routinely targeted in clinical practice. Recent data indicate that immunotherapy will be incorporated into first-line chemotherapy, but further research is required to refine patient selection. This review will summarize the clinical strategies being evaluated to utilize our knowledge of predictive biomarkers with reference to novel therapeutics, and discuss the barriers to implementing precision oncology in OG adenocarcinoma.</description><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - therapy</subject><subject>Biomarkers - metabolism</subject><subject>biomarkers of response</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>esophageal cancer</subject><subject>Esophageal Neoplasms - genetics</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - therapy</subject><subject>esophago-gastric adenocarcinoma</subject><subject>gastric cancer</subject><subject>gastro-esophageal junction cancer</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - administration & dosage</subject><subject>Immunoconjugates - administration & dosage</subject><subject>Immunotherapy - methods</subject><subject>Immunotherapy - trends</subject><subject>Precision Medicine - methods</subject><subject>Precision Medicine - trends</subject><subject>precision oncology</subject><subject>predictive biomarkers</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Review</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>targeted therapy</subject><subject>Trastuzumab - administration & dosage</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kc-P1SAQx4nRuD_06NVw9IIOU0pfLyZms7qbbOJFz4TSoQ_tgwrtJvvfy8tbN3rwNEP48AHmy9gbCe8RZfdhmYpAQBAAPTxj57JTSuxA4fPaK40CldRn7KKUHwAotYKX7KxREkFpec7sjc2RSglx4kNIB5t_Ui48eZ6pLCkW4mvi4bDkdF_bPWW7PPBCM7k1pMhD5FTSsrdTEpMtaw6O25Ficja7EKvwFXvh7Vzo9WO9ZN8_X3-7uhF3X7_cXn26E0413SpabH2jG-tI4mj7rm-gd34A6fu-laT9oGuVatA4StnRqHsLY-OlwqFrPTaX7OPJu2zDgUZHcc12NksO9VMPJtlg_t2JYW-mdG92qFvcHQXvHgU5_dqorOYQiqN5tpHSVgy2CjpsUUNFxQl1OZWSyT9dI8EcYzE1FnOMxRxjqfzbv9_2RP_JoQL9CfDbutXJu0DRkTmt6olQZ0n_kf8GzFSfEw</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Fong, Caroline Yk</creator><creator>Chau, Ian</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4409-9466</orcidid><orcidid>https://orcid.org/0000-0003-0286-8703</orcidid></search><sort><creationdate>20210701</creationdate><title>Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma</title><author>Fong, Caroline Yk ; Chau, Ian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - therapy</topic><topic>Biomarkers - metabolism</topic><topic>biomarkers of response</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>esophageal cancer</topic><topic>Esophageal Neoplasms - genetics</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - therapy</topic><topic>esophago-gastric adenocarcinoma</topic><topic>gastric cancer</topic><topic>gastro-esophageal junction cancer</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - administration & dosage</topic><topic>Immunoconjugates - administration & dosage</topic><topic>Immunotherapy - methods</topic><topic>Immunotherapy - trends</topic><topic>Precision Medicine - methods</topic><topic>Precision Medicine - trends</topic><topic>precision oncology</topic><topic>predictive biomarkers</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Review</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>targeted therapy</topic><topic>Trastuzumab - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fong, Caroline Yk</creatorcontrib><creatorcontrib>Chau, Ian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fong, Caroline Yk</au><au>Chau, Ian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>22</volume><issue>11</issue><spage>703</spage><epage>726</epage><pages>703-726</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>Advanced esophago-gastric (OG) adenocarcinomas have a high mortality rate and new therapeutic options are urgently required. Despite recent advances in understanding the molecular characteristics of OG cancers, tumor heterogeneity poses a challenge in developing new therapeutics capable of improving patient outcomes. Consequently, chemotherapy remains the mainstay of systemic treatment, with the HER2 being the only predictive biomarker routinely targeted in clinical practice. Recent data indicate that immunotherapy will be incorporated into first-line chemotherapy, but further research is required to refine patient selection. This review will summarize the clinical strategies being evaluated to utilize our knowledge of predictive biomarkers with reference to novel therapeutics, and discuss the barriers to implementing precision oncology in OG adenocarcinoma.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>34120461</pmid><doi>10.2217/pgs-2020-0090</doi><tpages>24</tpages><orcidid>https://orcid.org/0000-0002-4409-9466</orcidid><orcidid>https://orcid.org/0000-0003-0286-8703</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2416 |
| ispartof | Pharmacogenomics, 2021-07, Vol.22 (11), p.703-726 |
| issn | 1462-2416 1744-8042 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8265282 |
| source | PubMed Central |
| subjects | Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - therapy Biomarkers - metabolism biomarkers of response Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Camptothecin - administration & dosage Camptothecin - analogs & derivatives esophageal cancer Esophageal Neoplasms - genetics Esophageal Neoplasms - metabolism Esophageal Neoplasms - therapy esophago-gastric adenocarcinoma gastric cancer gastro-esophageal junction cancer Humans Immune Checkpoint Inhibitors - administration & dosage Immunoconjugates - administration & dosage Immunotherapy - methods Immunotherapy - trends Precision Medicine - methods Precision Medicine - trends precision oncology predictive biomarkers Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Review Stomach Neoplasms - drug therapy targeted therapy Trastuzumab - administration & dosage |
| title | Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A19%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Harnessing%20biomarkers%20of%20response%20to%20improve%20therapy%20selection%20in%20esophago-gastric%20adenocarcinoma&rft.jtitle=Pharmacogenomics&rft.au=Fong,%20Caroline%20Yk&rft.date=2021-07-01&rft.volume=22&rft.issue=11&rft.spage=703&rft.epage=726&rft.pages=703-726&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs-2020-0090&rft_dat=%3Cproquest_pubme%3E2540725260%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c437t-525f363ace12da979309cfb01f9951e6fb695114b62d117ed69a0d3f142b75f23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2540725260&rft_id=info:pmid/34120461&rfr_iscdi=true |